Vext Science (FRA:VV5) 1-Year Sharpe Ratio: 0.52 (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VV5 Vext Science Inc FRA:VV5
53 GF Score
Price €0.16
GF Value €0.16
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vext Science 1-Year Sharpe Ratio?

Vext Science FRA:VV5 -1.86% 53 1-Year Sharpe Ratio is 0.52 as of Sep. 03, 2026. GuruFocus rates FRA:VV5 with a GF Score™ of 53/100 and a GF Value™ of €0.16 (Fairly Valued). The stock has 4 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-03), Vext Science's 1-Year Sharpe Ratio is 0.52.

Vext Science  (FRA:VV5) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Vext Science 1-Year Sharpe Ratio Related Terms

FRA:VV5 vs ZTS: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vext Science 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vext Science's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Vext Science's 1-Year Sharpe Ratio falls into.


FRA:VV5
53GF Score
Vext Science Inc FRA:VV5
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vext Science 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.52 mean?
Vext Science (FRA:VV5) has a 1-Year Sharpe Ratio of 0.52 as of Sep. 03, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Vext Science and its competitors.
Is Vext Science's 1-Year Sharpe Ratio too high?
Vext Science's current 1-Year Sharpe Ratio is 0.52. Overall, Vext Science has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vext Science's 1-Year Sharpe Ratio compare to ZTS?
Vext Science's 1-Year Sharpe Ratio of 0.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Vext Science and its competitors. Vext Science's current 1-Year Sharpe Ratio is 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (FRA:VV5) is currently considered Fairly Valued. The stock's GF Value™ is €0.16, compared to a current price of €0.16 — trading 1.3% below its estimated fair value. The current 1-Year Sharpe Ratio is 0.52. Vext Science's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current 1-Year Sharpe Ratio is 0.52 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vext Science (FRA:VV5) Overvalued in 2026?

Based on GuruFocus' analysis, Vext Science stock appears to be undervalued. The current stock price of €0.16 is trading 1.3% below its estimated GF Value™ of €0.16. GuruFocus considers Vext Science to be Fairly Valued.

Key valuation signals for FRA:VV5:

  • 1-Year Sharpe Ratio: 0.52
  • GF Value™: €0.16 vs. price of €0.16 (1.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vext Science Business Description

Other Exchanges VEXTF:USAVEXT:Canada
Address 4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
53GF Score

Get the complete analysis for FRA:VV5

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.16
GF Value